Real‐world evidence to support regulatory decision‐making for medicines: Considerations for external control arms
Mehmet Burcu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Wei Zhou(Broad Institute), Nancy A Dreyer(IQVIA (United Kingdom)), Jessica M. Franklin(New England College of Optometry), Cathy W. Critchlow(University of Washington), Eleanor M. Perfetto(University of Maryland, Baltimore), Michael D. Blum(United States Food and Drug Administration)
Cited by 120
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
A Cohort Study of the Risk of Cervical Intraepithelial Neoplasia Grade 2 or 3 in Relation to Papillomavirus Infection
|New England Journal of Medicine|1992|952
Invasion of the Central Nervous System by <i>Treponema pallidum:</i> Implications for Diagnosis and Treatment
|Annals of Internal Medicine|1988|601
Diagnosis and clinical manifestations of bacterial vaginosis
|American Journal of Obstetrics and Gynecology|1988|557
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
|Proceedings of the National Academy of Sciences|2011|256